Literature DB >> 26662167

In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.

Dirk Luchtman1, René Gollan1, Erik Ellwardt1, Jérôme Birkenstock1, Kerstin Robohm1, Volker Siffrin1, Frauke Zipp1.   

Abstract

In multiple sclerosis (MS), a candidate downstream mechanism for neuronal injury is glutamate (Glu)-induced excitotoxicity, leading to toxic increases in intraneuronal Ca(2+) . Here, we used in vivo two-photon imaging in the brain of TN-XXL transgenic Ca(2+) reporter mice to test whether promising oral MS therapeutics, namely fingolimod, dimethyl fumarate, and their respective metabolites fingolimod-phosphate and monomethyl fumarate, can protect neurons against acute glutamatergic excitotoxic damage. We also assessed whether these drugs can protect against excitotoxicity in vitro using primary cortical neurons, and whether they can directly inhibit Glu release from pathogenic T-helper 17 lymphocytes. In vivo, direct and acute (1 h) administration of 100 mM Glu to the brainstem resulted in a rapid and significant up-regulation in neuronal Ca(2+) signaling as well as morphological excitotoxic changes that were attenuated by the NMDA-receptor antagonist MK801. Direct CNS administration of MS drugs prior to Glu significantly delayed or reduced, but did not prevent the neuronal Ca(2+) increase or morphological changes. In vitro, prolonged (24 h) treatment of primary neurons with the fumarates significantly protected against neurotoxicity induced by Glu as well as NMDA, similar to MK801. Furthermore, monomethyl fumerate significantly reduced Glu release from pathogenic T-helper 17 lymphocytes. Overall, these data suggest that MS drugs may mediate neuroprotection via excitotoxicity modulating effects. Evidence suggests MS pathogenesis may involve neuronal excitotoxicity, induced by local release of glutamate. However, current MS drugs, including dimethyl fumerate (DMF) and fingolimod (FTY720) are largely anti-inflammatory and not yet fully tested for their neuroprotective potential. Here, we show that the drugs, in particular DMF metabolite monomethyl fumerate (MMF), protect neurons by excitotoxicity modulating effects. Th17, T-helper 17.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  calcium; excitotoxicity; glutamate; multiple sclerosis; neuroprotection; two-photon imaging

Mesh:

Substances:

Year:  2016        PMID: 26662167     DOI: 10.1111/jnc.13456

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Glutamate, T cells and multiple sclerosis.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2017-02-24       Impact factor: 3.575

2.  β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.

Authors:  Katharina Birkner; Beatrice Wasser; Tobias Ruck; Carine Thalman; Dirk Luchtman; Katrin Pape; Samantha Schmaul; Lynn Bitar; Eva-Maria Krämer-Albers; Albrecht Stroh; Sven G Meuth; Frauke Zipp; Stefan Bittner
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

3.  Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis.

Authors:  Vanessa F Moreira Ferreira; Yanqing Liu; Brian C Healy; James M Stankiewicz
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-04-29

Review 4.  Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis.

Authors:  Soumya S Yandamuri; Thomas E Lane
Journal:  Front Immunol       Date:  2016-05-19       Impact factor: 7.561

5.  Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection.

Authors:  Björn Ambrosius; Kalliopi Pitarokoili; Lisa Schrewe; Xiomara Pedreiturria; Jeremias Motte; Ralf Gold
Journal:  J Neuroinflammation       Date:  2017-04-26       Impact factor: 8.322

6.  Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Authors:  Mahtab Ghadiri; Ayman Rezk; Rui Li; Ashley Evans; Felix Luessi; Frauke Zipp; Paul S Giacomini; Jack Antel; Amit Bar-Or
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-03-23

7.  NRF2 as an Emerging Therapeutic Target.

Authors:  Ian M Copple; Albena T Dinkova-Kostova; Thomas W Kensler; Karen T Liby; W Christian Wigley
Journal:  Oxid Med Cell Longev       Date:  2017-01-31       Impact factor: 6.543

Review 8.  Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis.

Authors:  Cecilia Rajda; Dániel Pukoli; Zsuzsanna Bende; Zsófia Majláth; László Vécsei
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923

Review 9.  Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.

Authors:  Elizabeth A Mills; Magdalena A Ogrodnik; Andrew Plave; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2018-01-23       Impact factor: 4.003

Review 10.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.